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co‑expression based cancer staging 
and application
Xiangchun Yu 2,3,5, Sha Cao 4, Yi Zhou3, Zhezhou Yu2* & Ying Xu1,3*
A novel method is developed for predicting the stage of a cancer tissue based on the consistency level 
between the co-expression patterns in the given sample and samples in a specific stage. The basis 
for the prediction method is that cancer samples of the same stage share common functionalities 
as reflected by the co-expression patterns, which are distinct from samples in the other stages. Test 
results reveal that our prediction results are as good or potentially better than manually annotated 
stages by cancer pathologists. This new co-expression-based capability enables us to study how 
functionalities of cancer samples change as they evolve from early to the advanced stage. New and 
exciting results are discovered through such functional analyses, which offer new insights about 
what functions tend to be lost at what stage compared to the control tissues and similarly what new 
functions emerge as a cancer advances. To the best of our knowledge, this new capability represents 
the first computational method for accurately staging a cancer sample. The R source code used in this 
study is available at GitHub (https ://githu b.com/yxchs pring /CECS).
We present a computational approach to stage accurately cancer tissues based on their RNA-seq data. The stage 
of a cancer is a key parameter for clinically characterizing the cancer. As a cancer advances, the disease generally 
evolves from a localized issue to a whole-body  problem1–3, not just in term of whether a cancer is metastasized 
or not, as cancer tends to persistently release certain molecules such as protons, cytokines and  polyamines4–6 
as well as “consume” certain molecules like sodium and iron, leading to substantial alterations of their blood 
concentrations over time. For some molecular species, such changes will trigger highly damaging responses by 
different organs throughout the body. Cachexia, i.e., loss of muscle cells throughout the body, is one consequence 
of such responses towards the advanced stage of a  cancer7–10 Intracellularly, considerable changes take place in 
metabolisms as a cancer evolves, giving rise to gradual and extensive metabolic reprogramming in  cancer11–14. 
Hence, cancers detected at different stages require distinct treatment plans. Therefore, accurate staging of a cancer 
is vitally important to the cancer patient and his/her physician.
Somewhat surprisingly, the clinical practice of cancer staging has not changed much in the past 40  years15–17 
as it is still done predominantly based on the morphology and the size of a cancer tissue, examined manually by 
cancer pathologists under microscope, assisted by limited protein biomarkers. One would intuitively expect that 
cancer staging nowadays should have been done in a more objective manner based on molecular data, knowing 
that cancer tissue omic data, particularly gene-expression data are easily obtainable in a financially viable man-
ner. However, the reality is: while gene-expression data represent the easiest to get and the most informative 
omic data for studying cancer tissues, they have not been widely used for cancer staging outside of laboratory 
 studies18–20. Published work is mostly on transcriptomic biomarkers for cancer prognostic  prediction21–27 rather 
than cancer staging.
A key challenge in achieving this goal comes from the reality that scientists have yet to identify genes whose 
(differential) expression patterns in cancer vs. controls are specifically associated with individual stages of a cancer 
type, and hence can be used for cancer-stage prediction. Our own analyses have discovered that co-expression 
patterns are considerably more informative than differential expressions of individual genes for cancer staging. 
Here we present a co-expression based cancer staging method. To the best of our knowledge, there are no pub-
lished studies that predict cancer stages using co-expression patterns of cancer tissues.
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A technical challenge in applying co-expression data for cancer staging is: how to derive co-expression 
information of genes in individual tissue samples since it generally requires multiple samples to infer such 
information while cancer staging needs to be done on individual tissues. Fortunately, Chen and co-workers have 
recently published a statistical method for inference of co-expressed genes in a single sample through compar-
ing the co-expressed genes in a set of reference samples and those in the reference set plus the current  sample28. 
Specifically, the approach assesses if the co-expression patterns among the reference samples are enhanced or 
weakened by including the sample into the reference set, namely an expanded set. A pair of genes in the new 
sample is considered as having the same co-expression pattern in the reference set and the expanded set if its co-
expression level in the latter is not statistically lower than in the former. Hence, when applied to all gene pairs, a 
set of co-expressed genes can be derived for the given sample with respect to the reference set. This method has 
been applied to solving a variety of co-expression analysis problems and found to be highly  effective28.
We have adapted and applied this approach to cancer tissue staging. Specifically, we assume that some sam-
ples for each stage of a cancer type are available, along with their genome-scale transcriptomic data, from which 
co-expression patterns can be derived reliably for each stage of the cancer type. Then a new sample is assigned 
to a stage if the sample’s co-expression pattern is most consistent with the co-expression patterns of the stage 
of the reference samples within a specified level of difference. We have applied this staging approach to eight 
cancer types in the TCGA database for stage prediction, representing all the cancer types that has at least ten 
cancer samples in each of the four stages. The consistency levels range from 71 to 95% across the eight cancer 
types we studied. The reason we have applied our method only to the TCGA data is that the data are collected 
from cancer tissue samples, rather than cell  lines29,30, with the highest data quality compared to other databases.
An important application of this methodology is to elucidate the functional differences between cancer sam-
ples at different stages, hence providing important and useful information regarding cancer evolution from early 
to the advanced stage. To do this, we have developed a new method for assessing the statistical significance of 
pathways enriched by a set of gene pairs rather than a set of genes as commonly done. By applying this method, 
we have examined what normal functions tend to disappear at what stage and what new functions may emerge 
at what stage of a cancer type. This functional analysis results have revealed novel understanding about cancer 
evolution, hence providing concrete examples for a profound postulation made by Otto Warburg 50 ago: “the 
highly differentiated cells are now transformed into fermenting anaerobes, which have lost all their body func-
tions and retain only the now useless function of growth”31–33.
Results
Gene expression data of eight cancer types, namely BRCA, COAD, HNSC, KIRC, KIRP, LUAD, STAD and THCA, 
are extracted from the TCGA database. Our cancer-stage prediction is conducted and assessed on these samples. 
The detailed information about these cancer data are given in the Methods section.
Identification of co-expressed genes. For each cancer type, edgeR in the R package is used to identify 
the differentially expressed genes (DEGs) using |log(FC)| > 2.5 and p value < 0.05 as the cutoffs. Pearson cor-
relation coefficient (PCC) is used to calculate the co-expression level between two genes. A pair of genes (x, y) is 






∣ > 2.5 with p value < 0.05 (see Methods). Table 1 summarizes 
the numbers of DEGs and CEGs for each cancer type at each stage.
Table 1.  The numbers of DEGs and CEGs in each of the eight cancer types.
Stage
#DEGs and 
#CEGs BRCA COAD HNSC KIRC KIRP LUAD STAD THCA
Stage 1 vs. control
#DEGs
Up 1,255 1,718 347 1,110 640 2,004 673 893
Down 512 729 975 594 735 129 670 228
#CEGs
Up 61,638 385,089 1,428 56,850 1,113 130,324 3,717 3,651
Down 1,690 11,763 26,804 920 2,564 121 15,338 600
Stage 2 vs. control
#DEGs
Up 1,564 1,581 547 1,399 700 1,268 662 662
Down 527 681 943 560 784 190 713 488
#CEGs
Up 14,410 143,619 634 62,299 14,452 3,102 1,892 7,835
Down 981 6,472 25,765 9,450 13,173 258 9,888 9,125
Stage 3 vs. control
#DEGs
Up 1,040 1,607 597 1,159 955 1,269 597 903
Down 553 588 949 739 640 217 744 289
#CEGs
Up 3,925 104,838 1,308 8,426 5,864 2,847 572 5,109
Down 1,912 6,200 16,024 2,306 784 1,007 7,295 2,074
Stage 4 vs. control
#DEGs
Up 818 1,035 798 1,325 657 1,097 504 932
Down 721 685 872 727 727 156 939 535
#CEGs
Up 7,386 4,597 542 18,161 9,068 14,427 952 3,449
Down 15,550 8,372 15,892 5,343 24,119 923 13,429 3,142
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An algorithm for representing cancer samples as co-expression networks. We have developed 
an algorithm for representing the gene-expression data of cancer tissue samples of a given cancer type as four 
stage-specific co-expression networks, one for each stage, and their perturbed networks when a new sample is 
added to the sample set of each stage. The level of perturbation due to inclusion of the new sample to each of the 
four co-expression networks, in general, will be significantly different between the network where the new sam-
ple intrinsically belongs and the three other networks. This serves as the basis of our cancer staging algorithm.
A co-expression network is built over samples in each stage of a given cancer type, consisting of only gene 
pairs that are highly co-expressed, where each gene pair is represented as an edge connecting two nodes denoting 
the two genes. When a new sample is added to the sample set of each stage, the co-expression levels of some gene 
pairs may change. Chen and co-authors have made the following  observation28: if two genes are co-expressed 
over a sample set, then adding a new sample to the set should not change their co-expression level significantly 
if their expression levels in the new sample are linearly consistent with those in the sample set; otherwise the 
co-expression level will decrease or remain at a low level. In addition, we have noted that cancer samples in the 
same stage tend to have a large collection of stage-specific co-expressed genes, used to execute the biological 
functions specific to the stage. By integrating these two insights, we have the following key observation: for a 
given co-expression network of a specific stage, adding a new sample that “intrinsically” belongs to the stage 
should not alter significantly the structure of the co-expression network; in contrast, when a sample is added 
to the sample set of a different stage, it will affect the co-expression levels of some gene pairs, hence altering the 
structure of the co-expression network. Our algorithm follows.
Step 1: Identification of DEGs for co-expression analyses. To ensure that the numbers of DEGs are approxi-
mately the same across different stages to avoid sample-size related bias, we have selected n DEGs with the 
largest variance for each stage, where n is the smallest number of DEGs in a stage across the four for the given 
cancer type.
Step 2: Construction of co-expression networks. Samples of each stage are divided into three groups: 30% as the 
reference, 40% for training, and 30% for testing. A co-expression network is constructed over the reference set 
for each of the four stages: each DEG is defined as a node and a pair of co-expressed DEGs above a PCC-based 
threshold (see METHODS) as an edge linking the two genes.
Step 3: Construction of a perturbed network over each sample set plus a new sample. For each co-expression 
network N built at Step 2 and a new sample s, calculate the PCC value for each co-expressed gene pair in N over 
the expanded sample set. If the relationship between the new PCC and the threshold is reversed compared to 
the original PCC, remove it from N if PCC > threshold; and otherwise add the edge to N.
Step 4: Data preparation for cancer-stage classifier training. For each new sample considered for cancer stag-
ing, represent each of its four perturbed networks as a one-dimensional vector: each pair of co-expressed genes 
in a co-expression network is given a fixed location in the vector, containing the PCC value or a 0.0 if the gene 
pair is removed in the perturbed network, hence allowing direct comparisons among such PCC-based vectors.
The detailed process of our algorithm is shown in Fig. 1.
A 4-way classifier for cancer staging. A machine learning-based classifier is trained to predict the stage, 
1 through 4, for a given cancer sample based on the PCC vectors defined in Sect. 2.1. Intuitively, if a new sample 
belongs to a specific stage, its perturbed network should be largely the same as the corresponding co-expression 
network; otherwise, the perturbed network may lose most of the stage-specific co-expressed genes, i.e., edges, 
from the original co-expression network.
We have used the following six machine-learning methods: Naive Bayes, treebag, C5.0, random forests (RF), 
random ferns (RFerns), and weighted subspace random forests (WSRF), respectively, to train the classifier.
Cancer stage prediction. Using the above cancer-staging algorithm, we have predicted stages for all the 
test samples of the eight cancer types. For each cancer type, we have randomly selected 30% of the samples from 
each stage and used them to derive the co-expression patterns; 40% for classification model training; and the 
remaining 30% for testing. Three-fold cross-validation with 100 repeats is used when training a classifier for each 
of the six machine learning methods. This process is iterated 10 times, and the average of the staging accuracy is 
used as the final evaluation results.
Table 2 summarizes the prediction results by C5.0, and prediction results by other methods are summarized 
in Supplementary Tables S1(1–5). We note that most of the machine learning methods give comparable results 
except for Naive Bayes and random Ferns, whose performances are poorer than the others as detailed in the 
Table S1.
To understand what might be the reasons for the inconsistent predictions by our method compared to the 
annotated stages in TCGA by pathologists, we have examined the prediction results for HNSC and STAD, the two 
cancer types with the worst overall prediction performance (Table 2). Tables 3 and 4 list, for each stage, the num-
bers of samples correctly predicted and of predicted to earlier or later stages of HNSC and STAD, respectively.
Since there is no ground truth for the actual stages of the cancer samples under consideration that can be used 
to assess the quality of the two staging methods, we have compared the distributions of the number of DEGs 
across samples at different “stages” by the two methods, as shown in Fig. 2. We see from the boxplots that our 
predicted stages give rise to boxplots with somewhat higher level of regularity compared to that of the annotated 
stages, hence providing one piece of evidence that our predicted stages, which is based on molecular information, 
might be more intuitively meaningful.
Figure 3 shows the similar information for STAD to that in Fig. 2. Analysis results on other cancer types are 
given in Supplementary Tables S2(1–6) and Figures S1(1–6). Overall, we consider that our predicted stages are 
probably as scientifically justified as the manually annotated stages by cancer pathologists or better.
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Figure 1.  An illustration of our algorithm. (A) Identification of DEGs between cancer versus control tissues 
at each stage. (B) Construction of co-expression networks for samples in each of the four stages with the DEGs 
obtained from step A. (C) Construction of perturbed networks over samples in each stage plus a new sample 
denoted by Ti. (D) Representation of each perturbed network as a feature vector needed for training, giving rise 
to four feature vectors concatenated into a long vector, which will be fed into a trainer as the feature vector for 
sample Ti.
Table 2.  Prediction performance of cancer stages using C5.0.
Stage Measure BRCA COAD HNSC KIRC KIRP LUAD STAD THCA
1
Sensitivity 0.7852 0.9227 0.6714 0.9519 0.9353 0.8795 0.24 0.9753
Specificity 0.983 0.9927 0.8783 0.9737 0.9 0.9227 0.9678 0.9172
2
Sensitivity 0.9409 0.9755 0.51 0.8938 0.6 0.74 0.8 0.9333
Specificity 0.9737 0.9641 0.9393 0.977 0.9928 0.9377 0.9257 0.9836
3
Sensitivity 0.7932 0.9237 0.4696 0.9639 0.7714 0.6667 0.7955 0.8212
Specificity 0.9722 0.9817 0.926 0.9933 0.9508 0.9688 0.7983 0.9422
4
Sensitivity 0.72 0.9667 0.8675 0.9292 0.8 0.4714 0.7273 0.4188
Specificity 0.922 0.9894 0.886 0.9809 0.9465 0.8965 0.889 0.9692
All
Accuracy 0.8768 0.9504 0.7283 0.9452 0.8707 0.7933 0.7078 0.8772
Kappa 0.7957 0.9293 0.546 0.9175 0.7436 0.6807 0.5696 0.7928
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Table 3.  The confusion matrix for predicted vs. annotated stage of HNSC.
Predicted/annotated Stage 1 Stage 2 Stage 3 Stage 4
Stage 1 4 5 2 1
Stage 2 2 14 5 5
Stage 3 1 0 16 9
Stage 4 0 1 0 62
Table 4.  The confusion matrix for predicted vs. annotated stage of STAD.
Predicted/actual Stage 1 Stage 2 Stage 3 Stage 4
Stage 1 8 1 2 0
Stage 2 0 19 3 0
Stage 3 4 11 37 2
Stage 4 3 1 2 9
Figure 2.  The distributions of the number of DEGs across samples at different “stages” by the manually 
annotated stages and our predicted stages. (a) The distribution of the numbers of DEGs (y-axis) in each 
annotated stage of HNSC. (b) The distribution of the numbers of DEGs in each predicted stage of HNSC.
Figure 3.  The distributions of the number of DEGs across samples at different “stages” by the manually 
annotated stages and our predicted stages. (a) The distribution of the numbers of DEGs in each annotated stage 
of STAD. (b) The distribution of the numbers of DEGs in each predicted stage of STAD.
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Pathways enriched by co-expressed genes. We have conducted pathway enrichment analyses over 
co-expressed genes in each stage of each of the eight cancers against the GO Biological Processes using our new 
scoring scheme (see “Methods”). Table 5 summarizes the numbers of the enriched pathways by co-expressed 
genes, with the pathway names given in Supplementary Tables S3-1 (controls), S3-2 (up-regulated), and S3-3 
(down-regulated), and information about pathways, hence functions, that disappear at each stage as well as new 
pathways that emerge at each stage in cancer versus controls, hence providing footprint information of cancer 
evolution.
We have also calculated the numbers of enriched pathways by co-expressed genes in controls, which (I) 
remain enriched throughout all stages of the cancer samples of each type; and (II) disappear by each stage of 
cancer samples, which do not appear again in a later stage, and in total for each cancer type. And we have also 
calculated (III) the number of new pathways that are not present in controls but present in earlier stages (1 and 
2) or advanced stages (3 and 4). All these are shown in Table 6 (I), (II) and (III), and the detailed pathways in 
cancer are listed in Supplementary Tables S4-1, S4-2 and S4-3. From these tables, we conclude:
 (i) it is somewhat surprising to see from Table S4-1 that different sets of functions remain unchanged 
throughout the development of a cancer type across the eight cancer types. For example, for BRCA, 
it is cell cycle and cell division activities that represent the predominant class of functions that remain 
unchanged throughout stages 1–4. And this is the only type of cancer with this or similar property. For 
COAD, it is three classes of functions, namely cellular stress, immune responses and tissue repair that 
remain unchanged throughout the evolution of the cancer. For HNSC, it is the combination of two func-
tional classes: tissue repair and cellular stress that remain unchanged throughout its evolution. For KIRC, 
no functional activities remain unchanged throughout its evolution. For KIRP, it is some developmental 
activities that remain unchanged. For LUAD, it is a few cell division activities that remain unchanged. 
And for STAD, it is predominantly immune responses that remain changed.
 (ii) from Table S4-2, we see the following: (1) pathway disappearance in cancer predominantly take place 
at stage 1 for six cancer types or stage 4 for two cancer types; and (2) most of the lost pathways tend to 
be cancer specific or at most shared by 2–3 cancer types except for a few, namely neutral lipid metabolic 
Table 5.  The numbers of pathways enriched by co-expressed genes in controls and at each stage. # CEPs is 
for the number of co-expressed gene pairs; Up is for the number of CEPs by up-regulated genes; and Down is 
similarly for down-regulated genes.
Stage #CEPs BRCA COAD HNSC KIRC KIRP LUAD STAD THCA
Stage 1 vs. control
Control 223 178 126 195 138 48 84 44
Up 120 13 74 22 4 46 53 82
Down 71 102 92 34 66 6 66 2
Stage 2 vs. control
Control 323 150 136 181 109 56 102 137
Up 166 25 39 135 66 54 18 16
Down 83 115 104 2 117 5 65 164
Stage 3 vs. control
Control 251 102 111 201 99 53 102 57
Up 143 25 27 265 81 41 35 85
Down 73 81 114 17 17 9 74 20
Stage 4 vs. control
Control 326 131 111 226 125 100 205 119
Up 135 38 27 313 99 110 34 56
Down 109 70 108 33 66 5 100 58
Table 6.  The number of enriched pathways in normal controls. Total on the second row is the number of 
pathways enriched by CEPs in control samples for each cancer type while Total under (II) is for the number of 
unique pathways enriched by CEPs across all cancer samples of each type.
#CEPs BRCA COAD HNSC KIRC KIRP LUAD STAD THCA
Total 442 274 168 355 261 133 264 257
(I) 69 29 78 0 3 5 34 9
(II)
Stage 1 91 78 20 103 68 21 21 16
Stage 2 64 31 7 7 17 3 20 20
Stage 3 16 8 1 9 9 0 19 14
Stage 4 56 11 0 11 9 7 85 40
Total 227 128 28 130 103 31 145 90
(III)
1–2 106 52 89 29 118 48 50 99
3,4 166 66 40 163 111 36 69 74
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process (shared by 6 cancer types), triglyceride metabolic process (shared by 5), acylglycerol metabolic 
process (by 5), response to drug (by 4), regulation of lipid localization (by 4), regulation of hormone 
levels (by 4), and organic anion transport (by 4), indicating that they may have negative effects on cancer 
development, hence selected for removal. The detailed list of the lost pathways by multiple cancer types 
is given in Table S5.
 (iii) from Table S4-3, we note that different cancer types tend to have different sets of emerging functions in 
cancer tissues vs. controls, which generally fall into the following classes: development and proliferation, 
immune related, stress related, migration related, metabolisms, tissue repair, and neural functions.
For BRCA, two classes of new functions account for the majority of the new functions, hence considered 
as predominant: development and proliferation and metabolisms in both early (stages 1 and 2) and advanced 
(stages 3–4) cancers.
For COAD, the two predominant functional classes are development and proliferation and stress related in 
both early and advanced cancers.
For HNSC, the new functions in early-stage cancer tissues are development and proliferation and immune 
related; and for the advanced tissues, only the former remains to be predominant.
For KIRC, no single class of functions stands out in the early stage; and immune related and development 
and proliferation stand out.
For KIRP, development and proliferation and metabolisms stand out in both the early and advanced cancer 
tissues.
For LUAD, development and proliferation and stress related functions stand out in the early stage; and the 
latter changes to neural activities in the advanced stage.
For STAD, tissue repair and immune related functions stand out in both early and advanced stages. In addi-
tion, development and proliferation become one of three standout functional classes with the other two in the 
advanced stage cancer tissues.
For THCA, immune and tissue repair stand out in the early stage; and the former changes to development 
and proliferation in the advanced stage.
Among these functions, development and proliferation related functions become increasingly predominant 
as a cancer advances from early to the advanced stage for virtually all cancer types. Similarly, the percentages of 
the following functions also increase as a cancer advances: stress, immune, and migration related.
Discussion
Our preliminary analyses strongly indicate that differential expressions of individual genes do not have adequate 
information for accurate cancer staging, and conserved co-expression patterns across cancer samples of the same 
stage do as we have demonstrated through here. This represents a key technical contribution to the research of 
cancer biology. We anticipate that a similar technique could be used for various similar problems such as cancer 
grading, classification of primary cancers that have metastasized vs. that have not.
Our prediction results are generally consistent with those assigned manually by cancer pathologists. In cases 
where our predictions are inconsistent with the manual annotation, further studies are needed as there are no 
clear indication of which “predictions” are more accurate between the two, although from one specific angle, our 
predictions seem to be biologically more meaningful. This should not be surprising since our prediction is based 
on functional commonalities shared by most of the cancer tissue samples of a specific stage. We anticipate that 
systematic applications of this new tool could lead to improved and biologically more meaningful staging schemes 
for different cancer types. For example, by studying how the overall functionality of cancer samples changes as 
a cancer advances, one could possibly identify key “jumps” in changes in the total functionality, which can be 
used to distinguish distinct phases of the evolution for specific cancer types, compared to the current staging 
schemes, which are largely based on sizes and morphology of tumors. Cancer staging based on such molecular 
functions could lead to improved treatment plans that can target at key functional hubs or weakest points in 
cancer metabolic networks at distinct phases.
Otto Warburg speculated fifty some years ago about cancer evolution as: “the highly differentiated cells are 
now transformed into fermenting anaerobes, which have lost all their body functions and retain only the now 
useless function of growth”31–33. Since then, very little has been established regarding what specific functions are 
lost as a cancer evolves. We consider that a scientific contribution made by this study is: we have provided some 
information along this direction, although our study is clearly primitive. A further study is planned to elucidate 
detailed functionalities of cancer at individual stage and of different types. Both functionalities shared by all or 
most of the cancer types and specific to individual cancer types are of great interests. Our co-expression based 
functional identification will prove to be a highly effective tool for conducting such studies.
Regarding the predominant new functions in cancer vs. controls as revealed by our analyses, it is under-
standable why development and proliferation represents a predominant one across a majority of the cancer 
types under study as cancer proliferation, unlike normal developmental processes, may require segments from 
multiple developmental programs, which might be activated possibly by different signals for different reasons 
such as the need for tissue repair, to have the cell-cycle genes activated and form a somewhat coordinated cell 
cycle process in support of continuous cell proliferation. Other emerging functions, such as immune, tissue 
repair, metabolisms and/or neural activities, tend to be less conserved across different cancer types. Hence it is 
natural to ask: are new functions in each cancer type relevant to or even possibly dictate the clinical behaviors 
of different cancer types such as more vs. less malignant cancers? Clearly, further and more in-depth analyses 
are clearly needed to address this question.
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conclusion
A new algorithm for cancer staging is developed based on co-expression patterns unique to specific cancer stages, 
along with a new method for assessing statistical significance of pathways enriched by co-expressed genes. Our 
test results have shown that our staging results are comparable with (or superior to) manual staging results by 
human pathologists. Highly exciting new insights are gained through our analyses of new pathways in cancer vs. 
controls as well as pathways that disappear gradually throughout the evolution of individual cancer types. We 
anticipate that the co-expression based analyses will prove to be an important direction for functional studies 
in cancer research.
Data and methods
Data. 14 cancer types were initially selected since this set of cancers has been used in our previous  studies34–37 
as they each have sufficiently large number of samples in TCGA, namely: BLCA, BRCA, COAD, ESCA, HNSC, 
KICH, KIRC, KIRP, LIHC, LUAD, LUSC, PRAD, STAD, and THCA. Here, we further require that each cancer 
type have at least ten samples for each stage, which leaves only eight cancer types: BRCA, COAD, HNSC, KIRC, 
KIRP, LUAD, STAD, THCA. Table 7 gives the detailed information for each of the eight cancer types.
Calculation of co-expressed genes. For a given set of cancer tissues and their transcriptomic data, we 
calculate the Pearson correlation coefficient (ρ) between each pair of expressed genes across the samples as fol-
lows:
where E(X) is the expected value of expression levels of gene x across all samples. A pair of genes is deemed to 
be co-expressed if  |ρ(X, Y)| > 0.7 with  p value < 0.05, where the  p value is calculated as follows:
with n being the number of samples.
Pathway enrichment. We have developed a new scoring scheme to assess the statistical significance of a 
pathway enriched by a set of co-expressed DEGs at a specific stage of a cancer type. For a pathway with n gene 
pairs containing k co-expressed gene pairs over a given set of cancer samples, the following hypergeometric 
 distribution38 is used to calculate the statistical significance of this pathway enriched by the k gene pairs where N 
gene pairs are differentially expressed in cancer vs. controls, of which K pairs of genes are co-expressed:
Data availability
The data used to support the findings of this study are openly available from TCGA database (https ://www.cance 
r.gov/about -nci/organ izati on/ccg/resea rch/struc tural -genom ics/tcga).
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Table 7.  The number of tissue samples for eight cancer types.
Cancer type Control Stage 1 Sage 2 Stage 3 Stage 4
BRCA 113 182 624 249 20
COAD 41 75 179 131 64
HNSC 44 25 70 78 261
KIRC 72 266 57 123 82
KIRP 32 172 22 51 15
LUAD 59 278 121 84 26
STAD 32 53 111 150 38
THCA 58 286 52 113 57
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